tetano
Editor, Senior Moderator
Int J Cardiol
. 2022 Jan 21;S0167-5273(22)00127-9.
doi: 10.1016/j.ijcard.2022.01.037. Online ahead of print.
Myocarditis after RNA-based vaccines for coronavirus
Alberto Cordero[SUP] 1 [/SUP], Diego Cazorla[SUP] 2 [/SUP], David Escribano[SUP] 2 [/SUP], Mª Amparo Quintanilla[SUP] 2 [/SUP], José Mª López-Ayala[SUP] 2 [/SUP], Patricio Pérez Berbel[SUP] 2 [/SUP], Vicente Bertomeu-González[SUP] 3 [/SUP]
Affiliations
Abstract
Background: The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest.
Methods: We performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected. Two were excluded (one was only in subjects with age 12-17 and other might had included subjects from a larger publication). We followed the PRISMA guidelines for abstracting data and assessing data quality and validity. Data was verified by 2 investigators.
Results: We analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034-0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19).
Conclusions and relevance: Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course.
Keywords: Covid vaccine; Myocarditis; RNA vaccine.
. 2022 Jan 21;S0167-5273(22)00127-9.
doi: 10.1016/j.ijcard.2022.01.037. Online ahead of print.
Myocarditis after RNA-based vaccines for coronavirus
Alberto Cordero[SUP] 1 [/SUP], Diego Cazorla[SUP] 2 [/SUP], David Escribano[SUP] 2 [/SUP], Mª Amparo Quintanilla[SUP] 2 [/SUP], José Mª López-Ayala[SUP] 2 [/SUP], Patricio Pérez Berbel[SUP] 2 [/SUP], Vicente Bertomeu-González[SUP] 3 [/SUP]
Affiliations
- PMID: 35074491
- DOI: 10.1016/j.ijcard.2022.01.037
Abstract
Background: The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest.
Methods: We performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected. Two were excluded (one was only in subjects with age 12-17 and other might had included subjects from a larger publication). We followed the PRISMA guidelines for abstracting data and assessing data quality and validity. Data was verified by 2 investigators.
Results: We analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034-0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19).
Conclusions and relevance: Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course.
Keywords: Covid vaccine; Myocarditis; RNA vaccine.